Effects of buspirone on dopamine dependent behaviours in rats

Indian Journal of Physiology and Pharmacology

Volumn 51, Issue 4, 2007, Pages 375-386

  Dhavalshankh, A G ^a   Jadhav, S A ^a   Gaikwad, R V ^a   Gaonkar, R K ^a   Thorat, V M ^a   Balsara, J J ^a  

^a KRISHNA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Apomorphine; Buspirone; Catalepsy; Dexamphetamine; Haloperidol; Rat; Stereotypy

Indexed keywords

APOMORPHINE; BUSPIRONE; DEXAMPHETAMINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; HALOPERIDOL;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; CONTROLLED STUDY; DRUG DEPENDENCE; MALE; NERVE CELL; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; RAT; STEREOTYPY;

ANIMALS; APOMORPHINE; BUSPIRONE; CATALEPSY; DEXTROAMPHETAMINE; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; MALE; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; STEREOTYPED BEHAVIOR;

EID: 38149138093     PISSN: 00195499     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Zifa E, Fillion G. 5-hydroxytryptamine receptors. Pharmacol Rev 1992; 44: 401-458.
2. Riblet LA, Taylor DP, Eison MS, Stanton HC. Pharmacology and neurochemistry of buspirone. J Clin Psychiatry 1982; 43: 11-16.
3. McMillen BA, Matthews RT, Sanghera MK, Shepard PD, German DC. Dopamine receptor antagonism by the novel antianxiety drug, buspirone. J Neurosci 1983; 3: 733-738.
4. McMillen BA, McDonald CC. Selective effects of buspirone and molindone on dopamine metabolism and function in the striatum and frontal cortex of the rat. Neuropharmacology 1983; 22: 273-278.
5. Seeman P. Brain dopamine receptors. Pharmacol Rev 1980; 32: 229-313.
6. Alander T, Grabowska-Anden M, Anden NE. Physiological significance of dopamine autoreceptors as studied following their selective blockade by molindone. J Pharm Pharmacol 1980; 32: 780-782.
7. Alander T, Anden NE, Grabowska-Anden M. Metoclopramide and sulpiride as selective blocking agents of pre and postsynaptic dopamine receptors. Naunyn Schmiedeberg's Arch Pharmacol 1980; 312: 145-150.
8. Balsara JJ, Gada VP, Nandal NV, Chandorkar AG. Psychopharmacological investigation of the monoamine oxidase inhibitory activity of molindone, a dihydroindolone neuroleptic. J Pharm Pharmacol 1984; 36: 608-613.
9. Ljungberg T, Ungerstedt U. Classification of neuroleptic drugs according to their ability to inhibit apomorphine-induced locomotion and gnawing : Evidence for two different mechanisms of action. Psychopharmacology 1978; 56: 239-247.
10. Ahtee L. Inhibition by apomorphine of the metoclopramide-induced catalepsy and increase in striatal homovanillic acid content. Br J Pharmacol 1975; 55: 381-385.
11. Braun AR, Barone P, Chase TN. Interaction of D-1 and D-2 dopamine receptors in the expression of dopamine agonist induced behaviors. In: Breese GR, Creese I, eds Neurobiology of central D-1 dopamine receptors. New York, Plenum Press 1986; 151-166.
12. Seiden LS, Sabol KE, Ricaurte GA. Amphetamine: Effects on catecholamine systems and behaviour. Annu Rev Pharmacol Toxicol 1993; 33: 639-677.
13. Wanibuchi F, Usuda S. Synergistic effects between D-1 and D-2 dopamine antagonists on catalepsy in rats. Psychopharmacology 1990; 102: 339-342.
14. Martres MP, Costentin J, Baudry M, Marcais H, Protais P, Schwartz JC. Long-term changes in the sensitivity of pre-and postsynaptic dopamine receptors in mouse striatum evidenced by behavioural and biochemical studies. Brow Res 1977; 136: 319-337.
15. Cooper JR, Bloom FE, Roth RH. In : The Biochemical Basis of Neuropharmacology 8th edn New York : Oxford University Press 2003; 225-270.
16. Balsara JJ, Bapat TR, Gada VP, Chandorkar AG. Small doses of apomorphine induce catalepsy and antagonize methamphetamine stereotypy in rats. Psychopharmacology 1982; 78: 192-194.
17. Costall B, Naylor RJ. Mesolimbic involvement with behavioural effects indicating antipsychotic activity. Eur J Pharmacol 1974; 27: 46-58.
18. Skolnick P, Weissman BA, Youdim MBH. Monoaminergic involvement in the pharmacological actions of buspirone. Br J Pharmacol 1985; 86: 637-644.
19. Cimino M, Ponzio F, Achilli G, Vantini G, Perego C, Algeri S, Garattini S. Dopaminergic effects of buspirone, a novel anxiolytic agent. Biochem Pharmacol 1983; 32: 1069-1074.
20. Baldessarini RJ, Tarazi FI. Pharmacotherapy of psychosis and mania. In Brunton LL, Lazo JS, Parker KL, eds Goodman and Oilman's The Pharmacological Basis of Therapeutics. New York, McGraw-Hill Companies Inc 2006; 461-500.
21. Ludwig CL, Weinberger DR, Bruno G, Gillespie M, Bakker K, LeWitt PA, Chase TN. Buspirone, Parkinson's disease, and the locus ceruleus. Clin Neuropharmacol 1986; 9: 373-378.
22. Sweetman SC. In : Martindale - The Complete Drug Reference 34th edn London. Pharmaceutical Press 2005; 672-673.
23. Queiroz CM, Alcantara FB, Yague AM, Bibancos T, Frussa - Filho R. Acute buspirone abolishes the expression of behavioral dopaminergic supersensitivity in mice. Braz J Med Biol Res 2002; 35: 237-242.
24. Conway P, Uretsky NJ. Enhanced stereotyped response to amphetamine after pretreatment with small doses of molindone. Neuropharmacology 1983; 22: 579-586.
25. Howard JL, Pollard GT, Craft RM, Rohrbach KW. Metoclopramide potentiates d-amphetamine-induced hypermotility and stereotypy in rats. Pharmacol Biochem Behav 1987; 27: 165-169.
26. Lyon M. Animal models of mania and schizophrenia. In Willner P ed Behavioural models in psychopharmacology : theoretical, industrial and clinical perspectives. Cambridge, Cambridge University Press 1991; 253-310.
27. Conceicao IM, Frussa-Filho R. Effects of a single administration of buspirone on catalepsy, yawning and stereotypy in rats. Braz J Med Biol Res 1993; 26: 71-74.
28. Dourish CT, Cooper SJ, Philips SR. Yawning elicited by systemic and intrastriatal injection of piribedil and apomorphine in the rat. Psychopharmacology 1985; 86: 175-181.